Valeant Plans Sales Rep Increase, DTC Campaign For Jublia
This article was originally published in The Pink Sheet Daily
Valeant has something to prove with the launch of Jublia, a topical treatment for toenail fungus, which it has held up as an example of its R&D strategy at work.
You may also be interested in...
EQT and Goldman Sachs to pay $8.5bn in Parexel’s second private equity buyout in four years.
Gurnet Point Capital and Patient Square Capital will buy Radius Health for approximately $890m, including a contingent value right dependent on sales growth for osteoporosis drug Tymlos.
Sanofi's Nestle talked to In Vivo about the company's early pipeline, the emerging technologies he thinks are most promising, and tapping external innovation.